Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
115.40
-0.81 (-0.70%)
Streaming Delayed Price
Updated: 1:45 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
Next >
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
↗
November 06, 2025
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Via
The Motley Fool
Topics
Regulatory Compliance
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
↗
October 30, 2025
The company's recent past featured robust growth, and it anticipates continued rises into the near future.
Via
The Motley Fool
Glaukos (GKOS) Q3 2025 Earnings Call Transcript
↗
October 30, 2025
Glaukos (GKOS) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday
↗
October 30, 2025
Via
Benzinga
Earnings Scheduled For October 29, 2025
↗
October 29, 2025
Via
Benzinga
Expert Outlook: Glaukos Through The Eyes Of 4 Analysts
↗
September 22, 2025
Via
Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
October 30, 2025
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 30, 2025
Via
Benzinga
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday
↗
October 30, 2025
Via
Benzinga
Earnings Scheduled For July 30, 2025
↗
July 30, 2025
Via
Benzinga
Earnings Scheduled For April 30, 2025
↗
April 30, 2025
Via
Benzinga
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
↗
February 24, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
↗
February 20, 2025
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
↗
October 30, 2025
Via
Benzinga
Why Glaukos Stock Jumped Over 20% After-Hours Today
↗
October 29, 2025
Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance.
Via
Stocktwits
What's going on in today's after hours session
↗
October 29, 2025
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Glaukos Corp (NYSE:GKOS) Soars on Strong Q3 2025 Earnings Beat and Robust 2026 Outlook
↗
October 29, 2025
Glaukos (GKOS) smashed Q3 2025 earnings forecasts, sending its stock soaring. The company posted record revenue and raised its 2025 and 2026 sales guidance.
Via
Chartmill
Topics
Earnings
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 29, 2025
Via
Benzinga
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
↗
October 27, 2025
Via
Benzinga
This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
↗
October 27, 2025
Via
Benzinga
Expert Outlook: Glaukos Through The Eyes Of 7 Analysts
↗
October 13, 2025
Via
Benzinga
Glaukos (GKOS) Q2 Revenue Jumps 30%
↗
August 01, 2025
Via
The Motley Fool
What 11 Analyst Ratings Have To Say About Glaukos
↗
May 02, 2025
Via
Benzinga
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
↗
May 01, 2025
Via
Benzinga
Forecasting The Future: 7 Analyst Projections For Glaukos
↗
April 16, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years
↗
March 28, 2025
Via
Benzinga
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
↗
February 24, 2025
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.
Via
Benzinga
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
↗
February 21, 2025
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
Via
Benzinga
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
↗
February 21, 2025
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.
Via
Benzinga
Wondering what's happening in today's after-hours session?
↗
February 20, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
